



13th December 2023

## Exciting times for Isogenica as Q4 comes to a close

As the year draws to a close, we have been reflecting on the events at Isogenica over the last quarter. We've had a busy few months, attending lots of networking and technical conferences, meeting and greeting friends old and new. We're happy to announce that one of our partnered assets has reached Phase I in Clinical Trials, and also the signing of two new strategic partnerships: one Licencing Agreement, and another an Asset Evaluation Deal. Finally, in a new series we're starting, our scientists give their thoughts on the question: "Why is cancer so hard?" as we look to answer some of the theory behind the science on drug development for cancer...

## How did the conferences go?

### ESMO, Barcelona



Conference season was truly upon us this quarter. Our Principal Scientist, Lurdes attended ESMO back in October, and discussed where the field of immuno-oncology might be heading in the near future. She gathered information from leaders in their fields about tackling toxicity and the cost of care, immunotherapies in the clinic, and the role of VHHs in oncology treatments.

Lurdes has compiled her thoughts and expert opinions on her learnings from ESMO on her LI, be sure to [check it out](#).

### Markets and Markets Next-Gen Immuno Oncology, Frankfurt

Isogenica's CEO, Bill Eldridge took to the stage at the Markets and Markets Next-Gen Immuno Oncology conference in Frankfurt early in Oct. His talk, titled "Synthetic VHHs as Building Blocks for Bi-specific T Cell Engagers" covered how VHHs are the perfect building blocks for various partnered assets, and further developing Isogenica's bi-specifics pipeline. Read his key takeaways [here](#).



### National Institute for Health, FNLCR

"Smaller, Better, Faster, Stronger - Highly Specific VHH Antibodies from Synthetic Libraries



Marion Cubitt had the honour of visiting the Frederick National Laboratory for Cancer Research (FNLCR) as a guest to present a talk on VHHs in October, entitled "Smaller, better, faster, stronger," where she covered the ins and outs of everything VHH from start to finish.

We have been working with the [FNLCR on a multi-project contract](#) aiming to develop molecules that can be used in clinical laboratory assays to measure biomarkers correlated with the molecular effectiveness of cancer immuno-oncology agents.

### BioEurope, Munich



Our Director of Business Development, David Mead and Alliances Manager, Claudia Fernandes, both attended BioEurope this November in the beautiful Residenz München, making new acquaintances and discussing with potential new connections about our [VHH discovery opportunities](#).

### Nordic Life Science Days, Copenhagen; Jefferies, London; Genesis, London



**Thursday 30th November, 14.45-15.15:  
Thematic Session hosted by Isogenica**

Come and speak to Director of Business Development, David Mead, PhD, to learn all about what Isogenica does, and how Isogenica can help you integrate high-quality VHH antibodies into your discovery projects



But that wasn't the only event our Director of Business, Dave Mead attended this quarter. Dave has been busy at partnering and business conferences throughout the last few months.

Some highlights include giving a sponsored talk at [Nordic Life Science Days](#) in Copenhagen by the British Embassy about our work at Isogenica and our VHH services. Then there was [Jefferies in London](#) to network and discuss commercial futures after a period of uncertainty following the pandemic, and finally, [Genesis](#) where Dave spoke with leaders in the field about key trends and deal making in the biotech industry.





## ELRIG Drug Discovery, Liverpool



Finally, we saw our KTP Associate, Ben Wagstaffe, and two of our Scientists, Kate Jones and Ziqian Yan attend ELRIG, where they were excited to listen to the ML-based talks, thinking to the future of incorporating ML with VHH library building.

## Isogenica announces two Pioneering Collaborations with an Antibody Research and License Agreement, and an Asset Evaluation Deal

We're proud to announce two new collaborations this quarter with leading UK and US biotech companies.

The first being an Antibody Research and Licence Agreement, leveraging the expertise and resources of both Isogenica and the undisclosed biotechnology company to propel the field of antibody research forward.

Isogenica announces two Pioneering Collaborations with an Antibody Research and License Agreement, and an Asset Evaluation Deal

NOV 30, 2023



The collaboration will drive joint research initiatives, combining the strengths of both companies to explore novel approaches in antibody development and application.


Additionally, Isogenica has entered into an Asset Evaluation Deal with another leading company. This agreement underscores Isogenica's dedication to collaborative research and development, with a focus on the controlled transfer of tangible research materials.

Details regarding specific projects, timelines, and financial terms of both agreements remain confidential.

## Why is cancer so hard?

A new series we are conducting with our scientists at Isogenica entitled, "Why is cancer so hard?" explores the theory behind what makes cancer so difficult to solve.

In our first episode, we asked Marion Cubitt, our Director of Discovery her view on the problem.



She discussed the theory of 'mutational burden' and how cancer is constantly mutating and evolving to outrun its host's immune system.

Similar to antibiotic resistance, cancer can respond to treatments targeting specific genetic mutations which exert a selection pressure on the tumour, leading to the emergence of subclones resistant to that treatment.

One solution to this issue is refining and perfecting the initial treatments to ensure maximum effectiveness the first time round.

Stay tuned on our LI to keep up with new episodes on What Makes Cancer so Hard? to hear more about it from our team of dedicated scientists.

## Christmas is among us!



We're celebrating at Great Chesterford this week with a Christmas lunch out for the team after a morning of wrapping up our objectives for this quarter at our OKR meet. It's been a busy year for us and one we're very grateful for.

We've gotten to go to numerous partnering events and scientific conferences, signed some new exciting deals, and continued the work with our valued partners and collaborators.

Merry Christmas to all our readers and see you in the new year!



Our mailing address is:

Want to change how you receive these emails?

you can [update your preferences](#) or [unsubscribe from this list](#).